Targeting cyclin D‐CDK4/6 increases the survival of patients with estrogen receptor positive breast cancer and in gastric cancer cells, inhibition of CDK4/6 with Palbociclib induces senescence or death, whereas in cells that express pRB and p53, it induces autophagy (Brown et al., 2012, Valenzuela et al., 2017). The gene discussed is CDK4; the disease is gastric cancer.